CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...

Related Keywords

Spain ,Beerse ,Region Flamande ,Belgium ,Edmond Chan ,Drug Administration ,European Union ,Committee For Orphan Medicinal Products ,Janssen Cilag International ,European Medicines Agency ,European Commission ,Johnson ,Area Lead Haematology ,Johnson Innovative ,New England Journal ,Professor Jes ,San Miguel ,Translational Medicine ,Universidad De Navarra ,Jordan Schecter ,Vice President ,Disease Area Leader ,Multiple Myeloma ,Orphan Medicinal Products ,Product Characteristics ,Innovative Medicine ,